Emiplacel

Summary

Emiplacel (CHEMBL4297243) is a phase-3 clinical-stage cell; indicated across 8 conditions including ischemic disease and hip fracture.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Cell
• Indications: 8 conditions
• Clinical trials: 9

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297243
Name	Emiplacel
Type	Cell
Max phase	3

Also known as: Emiplacel, PLX-PAD, PLXPAD, EMIPLACEL

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

8 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
ischemic disease	3	MONDO:0005053	EFO:0000556
hip fracture	3	MONDO:0005327	EFO:0003964
intermittent vascular claudication	2	MONDO:0005295	EFO:0003876
peripheral arterial disease	2	MONDO:0005386	EFO:0004265
severe acute respiratory syndrome	2	MONDO:0005091	EFO:0000694
injury	1	MONDO:0021178	EFO:0000546
pulmonary arterial hypertension	1	MONDO:0015924	EFO:0001361

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 9.

Phase distribution

Phase	Trials
PHASE3	2
PHASE2	2
PHASE1	2
Not specified	2
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03006770	PHASE3	COMPLETED	Efficacy, Tolerability and Safety of Intramuscular Injections of PLX PAD for the Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization
NCT03451916	PHASE3	COMPLETED	Treatment of Muscle Injury Following Arthroplasty for Hip Fracture (HF)
NCT01525667	PHASE1/PHASE2	COMPLETED	Safety and Efficacy of IM Injections of PLX-PAD for the Regeneration of Injured Gluteal Musculature After Total Hip Arthroplasty
NCT04389450	PHASE2	TERMINATED	Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19
NCT04614025	PHASE2	TERMINATED	Open-label Multicenter Study to Evaluate the Efficacy of PLX-PAD for the Treatment of COVID-19
NCT00951210	PHASE1	COMPLETED	Safety of Intramuscular Injections (IM) of Allogeneic PLX-PAD Cells for the Treatment of Critical Limb Ischemia (CLI)
NCT01795950	PHASE1	TERMINATED	Safety Study of PLX-PAD Cells to Treat Pulmonary Arterial Hypertension (PAH)
NCT03746899	Not specified	AVAILABLE	Expanded Access for Treatment Use of PLX-PAD in Critical Limb Ischemia (CLI)
NCT03886506	Not specified	NO_LONGER_AVAILABLE	Expanded Access Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).